Skip to content
New Era Korea Daily한국어로 보기

Alteogen to absorb BioLogics in all-stock merger to build fully integrated drugmaker

Alteogen will take over its 62.9-percent-owned subsidiary Alteogen BioLogics in a small-scale merger, issuing 600,477 new shares to combine research, manufacturing, clinical and sales operations in one company.

By New Era Daily AIAI-writtenPublished
Illustration: Alteogen to absorb BioLogics in all-stock merger to build fully integrated drugmaker
Corporate news and earnings — Illustration: New Era Korea Daily · AI-generated

Alteogen said Thursday it will absorb its subsidiary Alteogen BioLogics in a small-scale all-stock merger, a step the company says is meant to combine drug discovery, manufacturing and commercialization in a single fully integrated biopharmaceutical business.

The merger ratio is one Alteogen share for every 0.1679581 shares of Alteogen BioLogics, and Alteogen will issue 600,477 new shares to complete the deal. Alteogen already owns 62.9 percent of BioLogics. The largest shareholder will hold 18.9 percent of the combined company. The merger agreement was signed on Oct. 7.

BioLogics reported 20.5 billion won ($15.3 million) in revenue and 6.3 billion won ($4.71 million) in net profit for the first half of 2026, according to the filing.

The merger brings BioLogics' drug candidates and commercial operations under the parent. Those include ALT-L9, an Eylea biosimilar that has completed a global Phase 3 trial and won European approval, and ALTS-OP01, a multi-target treatment candidate for retinal disease that is being prepared for a global Phase 1 study. BioLogics also sells Trigel injection and has built a nationwide sales network through that product.

"Alteogen is securing growth engines to follow Hybrozyme and is preparing to invest in its own production facilities, working toward becoming a company that handles everything from research and development to production and sales," the company said. "We concluded that, alongside these investments, promptly integrating the subsidiary's pipeline and its clinical, licensing and sales capabilities was the most effective approach."

"This merger is a turning point for Alteogen, which has grown on the Hybrozyme platform, to expand its business into the development and commercialization of its own products," an Alteogen official said.

The company said the merged entity will pursue a "fully integrated biopharmaceutical company" model, known by the acronym FIBCO, covering the entire chain from identifying new drug candidates to manufacturing and selling finished products.

What this article is based on

Every fact in this article can be checked against the primary documents below.

  1. Other합병 일정·절차· alteogenbiologics.com· accessed Nov. 12, 2026
  2. Regulatory filing알테오젠 [기재정정]주요사항보고서(회사합병결정)· DART· accessed Nov. 12, 2026
  3. Regulatory filing주력 사업· DART· accessed Nov. 12, 2026
  4. Other합병 배경 — 왜 지금인가· alteogen.com· accessed Nov. 12, 2026
  5. Other[발언] 알테오젠· alteogen.com· accessed Nov. 12, 2026
  6. Other수익가치 산정 의미· alteogen.com· accessed Nov. 12, 2026
  7. Other[발언] 전태연· alteogen.com· accessed Nov. 12, 2026

© New Era Korea Daily. All rights reserved.